Contents: GLP-1 (Sema) 5 mg (1 vial) + CJC-1295 (no DAC) / Ipamorelin 5/5 mg (2 vials) · Purity: ≥99% by reverse-phase HPLC · Identity: ESI-MS confirmed
The MINMORPH Kit combines two research directions in one set: metabolic signaling, through GLP-1 (Sema) (a GLP-1 receptor agonist), and the growth-hormone axis, through a CJC-1295/Ipamorelin blend. It provides one GLP-1 (Sema) vial plus two blend vials, each supplied separately with its own documentation.
Structure & Identity
The kit contains distinct components. GLP-1 (Sema) is a modified GLP-1 receptor agonist (CAS 910463-68-2). Each blend vial contains CJC-1295 (no DAC / Modified GRF 1-29), a GHRH analog, plus ipamorelin, a selective growth-hormone secretagogue (CAS 170851-70-4). Each keeps its own structure and receptor target.
Research Background
The kit spans metabolic and growth-hormone-axis research.
- GLP-1 signaling. GLP-1 (Sema) is a GLP-1 receptor agonist studied in metabolic research [PMID: 34626851].
- GLP-1 mechanism. GLP-1-based signaling mechanisms are an active area [PMID: 40466247].
- GHRH arm. CJC-1295 acts at the GHRH receptor for GH/IGF-1 stimulation [PMID: 16352683].
- Ghrelin arm. Ipamorelin is a selective GH secretagogue [PMID: 9849822].
- Combined rationale. The kit spans metabolic and growth-hormone-axis research.
These are research contexts, not approved uses, and the kit is intended for laboratory study.
Specifications
| Attribute |
Value |
| Product type |
Kit (three vials) |
| Vial 1 |
GLP-1 (Sema) (GLP-1 agonist), 5 mg (CAS 910463-68-2) |
| Vials 2-3 |
CJC-1295 (no DAC) / Ipamorelin blend, 5 mg / 5 mg each |
| Purity |
≥99% by reverse-phase HPLC (each) |
| Identity |
Confirmed by ESI mass spectrometry |
| Physical form |
Lyophilized powder |
| Storage |
-20°C, protected from light |
| Solubility |
Soluble in bacteriostatic or sterile water |
| Classification |
Research use only |
Storage & Handling
Keep all sealed vials frozen at -20°C and shielded from light until use. After reconstitution, store each solution at 2-8°C and use it within about two weeks. Warm a vial to room temperature before opening, and avoid repeated freeze-thaw cycles so each peptide stays intact.
Storage and Handling Guide
Quality Assurance
The components of the MINMORPH Kit are produced under research-grade manufacturing controls and verified by an independent lab before release. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with testing carried out by third-party laboratories, including Janoshik Analytical and domestic US labs. Each vial has its own published batch-specific certificate of analysis.
Quality & Testing
Frequently Asked Questions
What is in the MINMORPH Kit?
Three vials: one GLP-1 (Sema) 5 mg, plus two vials of a CJC-1295 (no DAC)/Ipamorelin 5/5 mg blend. The kit is studied across metabolic and growth-hormone-axis research and supplied for research use only.
Which CJC-1295 is included, DAC or no DAC?
The no-DAC form (Modified GRF 1-29), a shorter-acting GHRH analog. It is combined with ipamorelin in each blend vial.
Why combine a GLP-1 peptide with GH-axis peptides?
It brings metabolic-signaling research (GLP-1 (Sema)) together with growth-hormone-axis research (CJC-1295 and ipamorelin) in one set.
Are the peptides combined in one vial?
GLP-1 (Sema) is its own vial; CJC-1295 and ipamorelin are pre-combined in each of the two blend vials. So the kit has three vials total.
Is the MINMORPH Kit FDA approved?
No. None of the components is FDA approved. The kit is a research-use-only preparation, not for human or veterinary use.
Does each vial have its own COA?
Yes, each vial is tested and publishes its own batch-specific certificate of analysis.
How should the kit be stored?
Keep all powders frozen at -20°C and protected from light. Once reconstituted for research, store each solution at 2-8°C and use within about two weeks.
How are the components verified?
Each is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab.
References
- GLP-1 physiology informs the pharmacotherapy of obesity. 2022. PMID: 34626851.
- Prolonged stimulation of growth hormone (GH) and IGF-I secretion by CJC-1295. 2006. PMID: 16352683.
- Ipamorelin, the first selective growth hormone secretagogue. 1998. PMID: 9849822.
